Patent application number | Description | Published |
20090023169 | High throughput sarcomeric assay - The present invention provides high throughput screening systems for identifying compounds that modulate the biological activity of a biochemically functional sarcomere. The method can be performed in plurality simultaneously with fluorescence or absorbance readouts. | 01-22-2009 |
20090029344 | Compositions and assays utilizing ADP or phosphate for detecting protein modulators - Described herein are methods which identify candidate agents as binding to a protein or as a modulator of the binding characteristics or biological activity of a protein. Generally, the methods involve the use of ADP or phosphate. The assays can be used in a high throughput system to obviate the cumbersome steps of using gels or radioactive materials. | 01-29-2009 |
20090029345 | MODULATING SKELETAL MUSCLE - Methods of identifying skeletal muscle activators are provided. Methods of activating skeletal muscle using skeletal muscle activators are also provided. | 01-29-2009 |
20090117534 | COMPOSITIONS AND ASSAYS UTILIZING ADP OR PHOSPHATE FOR DETECTING PROTEIN MODULATORS - Described herein are methods which identify candidate agents as binding to a protein or as a modulator of the binding characteristics or biological activity of a protein. Generally, the methods involve the use of ADP or phosphate. The assays can be used in a high throughput system to obviate the cumbersome steps of using gels or radioactive materials. | 05-07-2009 |
20090176307 | Compounds, Compositions and Methods - Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure. | 07-09-2009 |
20090247544 | Certain Chemical Entities, Compositions and Methods - Certain substituted urea derivatives modulate diskeletal myosin, skeletal actin, skeletal tropomyosin, skeletal troponin C, skeletal troponin I, skeletal troponin T, and skeletal muscle, including fragments and isoforms thereof, as well as the skeletal sarcomere, and are useful in the treatment of obesity, sarcopenia, wasting syndrome, frailty, muscle spasm, cachexia, neuromuscular diseases (e.g., amyotrophic lateral sclerosis, spinal muscular atrophy, familial or acquired myopathies or muscular dystrophies), post-surgical and post-traumatic muscle weakness, and other conditions. | 10-01-2009 |
20100069370 | COMPOUNDS, COMPOSITIONS AND METHODS - Certain substituted sulfonamide derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure. | 03-18-2010 |
20110014212 | Certain Chemical Entities, Compositions and Methods - Provided is a method of treating myasthenia gravis in a patient by administering to the patient an effective amount of a skeletal muscle troponin activator, or a pharmaceutically acceptable salt thereof. | 01-20-2011 |
20110112154 | Compounds, compositions and methods - Certain substituted sulfonamide derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure. | 05-12-2011 |
20120088779 | HETEROCYCLIC SULFONAMIDES - Certain substituted sulfonamide derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure. | 04-12-2012 |
20120232092 | HETEROCYCLIC SULFONAMIDES - Certain substituted sulfonamide derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure. | 09-13-2012 |
20130053389 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS - Provided is a method of treating myasthenia gravis in a patient by administering to the patient an effective amount of a skeletal muscle troponin activator, or a pharmaceutically acceptable salt thereof. | 02-28-2013 |
20130210733 | METHODS OF TREATING LUNG DISEASE - Provided herein are methods of treating lung disease in a subject by administering to the subject a therapeutically effective amount of a mitotic kinesin inhibitor, optionally in combination with another therapy. | 08-15-2013 |
20130267537 | HETEROCYCLIC SULFONAMIDES - Certain substituted sulfonamide derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure. | 10-10-2013 |
20140243344 | COMBINATION ALS THERAPY - Provided is a method for treating ALS in a subject, comprising administering to the subject a therapeutically effective amount of riluzole and a therapeutically effective amount of CK-2017357. Also provided are methods of reducing the variability of riluzole exposure (e.g., C | 08-28-2014 |
20140303366 | Certain 1H-Imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-Imidazo[4,5-b]pyrazin-2-ols and Methods for Their Use - Provided is a method of treating myasthenia gravis in a patient by administering to the patient an effective amount of a skeletal muscle troponin activator, or a pharmaceutically acceptable salt thereof. | 10-09-2014 |